Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) is recommended for larynx-preserving treatment of locally advanced hypopharyngeal cancer (LAHC). However, the conventional evaluation of response is not robust enough to predict the outcome of subsequent treatments. This study aimed to develop an imaging biomarker using changes in radiomic features in invasive tumor front (ITF) by IC to predict treatment outcome of subsequent CCRT in LAHC.
Methods:
From 2006 to 2018, 59 computed tomography (CT) scan images before and after IC in patients with LAHC were used to contour the gross tumor volumes (GTVs). A total of 48 delta-volume radiomics features were acquired from the absolute spatial difference of GTVs (delta-GTV) before and after IC, conceptually representing a consistent portion of ITF. Least absolute shrinkage and selection operator regression (LASSO) was used to select features for establishing the model generating radiomic score (R score).
Results:
A model including 5 radiomic features from delta-GTV to predict better progression-free survival (PFS) of patients receiving subsequent CCRT was established. The R score was validated with all datasets (area under the curve 0.77). Low R score (<–0.16) was associated with improved PFS (p < 0.05).
Conclusions:
The established radiomic model for ITF from radiomic features of delta-GTV after IC might be a potential imaging biomarker for predicting clinical outcome of subsequent CCRT in LAHC.
Department of Veterans Affairs Laryngeal Cancer Study Group, WolfGTFisherSG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med1991; 324: 1685–1690.
2.
LefebvreJLChevalierDLuboinskiB, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial: EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst1996; 88: 890–899.
3.
ForastiereAAGoepfertHMaorM, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med2003; 349: 2091–2098.
4.
TakesRPStrojanPSilverCE, et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck2012; 34: 270–281.
5.
ChengCTLinCYHung-Chun ChengS, et al. Survival benefit of surgical approach for advanced oropharyngeal and hypopharyngeal cancer: a retrospective analysis. Head Neck2017; 39: 2104–2113.
6.
TsouYALinMHHuaCH, et al. Survival outcome by early chemoradiation therapy salvage or early surgical salvage for the treatment of hypopharyngeal cancer. Otolaryngol Head Neck Surg2007; 137: 711–716.
7.
RohJLKimJSKangBC, et al. Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas. J Surg Oncol2014; 110: 869–875.
8.
GatenbyRAGroveOGilliesRJ.Quantitative imaging in cancer evolution and ecology. Radiology2013; 269: 8–14.
9.
LambinPLeijenaarRTHDeistTM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol2017; 14: 749–762.
10.
ParekhVJacobsMA.Radiomics: a new application from established techniques. Expert Rev Precis Med Drug Dev2016; 1: 207–226.
11.
BànkfalviAPiffkòJ.Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J Oral Pathol Med2000; 29: 291–298.
12.
KocakBDurmazESAtesE, et al. Radiogenomics of lower-grade gliomas: machine learning-based MRI texture analysis for predicting 1p/19q codeletion status. Eur Radiol2020; 30: 877–886.
13.
NasiefHZhengCSchottD, et al. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. NPJ Precis Oncol2019; 3: 25.
14.
SunWHuangJQChenL, et al. Peripheral inflammation markers of chemosensitivity to induction chemotherapy in hypopharyngeal cancer patients. ORL J Otorhinolaryngol Relat Spec2019; 81: 82–91.
15.
YangBGuoLLuG, et al. Radiomic signature: a non-invasive biomarker for discriminating invasive and non-invasive cases of lung adenocarcinoma. Cancer Manag Res2019; 11: 7825–7834.
16.
ZhangQCaoJZhangJ, et al. Differentiation of recurrence from radiation necrosis in gliomas based on the radiomics of combinational features and multimodality MRI images. Comput Math Methods Med2019; 2019: 2893043.
17.
JeonSHSongCChieEK, et al. Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer. Radiat Oncol2019; 14: 43.
18.
CunliffeAArmatoSG3rdCastilloR, et al. Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development. Int J Radiat Oncol Biol Phys2015; 91: 1048–1056.
19.
CarvalhoSLeijenaarRTHTroostEGC, et al. Early variation of FDG-PET radiomics features in NSCLC is related to overall survival: the “delta radiomics” concept. Radiother Oncol2016; 118: S20–S21.
20.
RaoSXLambregtsDMSchnerrRS, et al. CT texture analysis in colorectal liver metastases: a better way than size and volume measurements to assess response to chemotherapy?United Eur Gastroenterol J2016; 4: 257–263.
21.
FaveXZhangLYangJ, et al. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer. Sci Rep2017; 7: 588.
22.
NiocheCOrlhacFBoughdadS, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res2018; 78: 4786–4789.
23.
ZwanenburgAVallièresMAbdalahMA, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology2020; 295: 328–338.
24.
TunaliIHallLONapelS, et al. Stability and reproducibility of computed tomography radiomic features extracted from peritumoral regions of lung cancer lesions. Med Phys2019; 46: 5075–5085.
25.
PiazzeseCFoleyKWhybraP, et al. Discovery of stable and prognostic CT-based radiomic features independent of contrast administration and dimensionality in oesophageal cancer. PLOS One2019; 14: e0225550.
26.
KimJ-H.Estimating classification error rate: repeated cross-validation, repeated hold-out and bootstrap. Comput Stat Data Analysis2009; 53: 3735–3745.
27.
FriedmanJHHastieTTibshiraniR.Regularization paths for generalized linear models via coordinate descent. J Stat Softw2010; 33: 22.
EfronB.An Introduction to the Bootstrap. Chapman and Hall/CRC; 1994.
30.
SunRLimkinEJVakalopoulouM, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol2018; 19: 1180–1191.
31.
BramanNMEtesamiMPrasannaP, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res2017; 19: 57.
32.
YanagiTShibamotoYOginoH, et al. Definitive radiotherapy following induction chemotherapy for hypopharyngeal cancer: selecting candidates for organ-preserving treatment based on the response to induction chemotherapy. Kurume Med J2016; 62: 1–8.
33.
LiuSFangJMaH, et al. Rational choice of induction chemotherapy-based larynx preservation for hypopharyngeal cancer. Acta Otolaryngol2018; 138: 1146–1153.
34.
HouTCDaiKYWuMC, et al. Bio-physic constraint model using spatial registration of delta 18F-fluorodeoxyglucose positron emission tomography/computed tomography images for predicting radiation pneumonitis in esophageal squamous cell carcinoma patients receiving neoadjuvant chemoradiation. Onco Targets Ther2019; 12: 6439–6451.
35.
AdelsteinDJLiYAdamsGL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol2003; 21: 92–98.
36.
TaylorSGtMurthyAKVannetzelJM, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol1994; 12: 385–395.
37.
SuntharalingamMHaasMLConleyBA, et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys2000; 47: 49–56.
38.
BonnerJAHarariPMGiraltJ, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol2010; 11: 21–28.
39.
SakaguchiMMaebayashiTAizawaT, et al. Clinical outcomes of hypopharyngeal cancer receiving definitive radiotherapy with concurrent chemotherapy. Anticancer Res2017; 37: 941–947.
40.
ChowLQMHaddadRGuptaS, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol2016; 34: 3838–3845.
41.
CohenEEWSoulièresDLe TourneauC, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet2019; 393: 156–167.
42.
FerrisRLBlumenscheinGJr.FayetteJ, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med2016; 375: 1856–1867.
43.
BindeaGMlecnikBTosoliniM, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity2013; 39: 782–795.
44.
DwivediAKMallawaarachchiIAlvaradoLA.Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method. Stat Med2017; 36: 2187–2205.
45.
WangZ.Comparison of sample size by bootstrap and by formulas based on normal distribution assumption. Ther Innov Regul Sci2019; 53: 170–175.
46.
EfronB.Bootstrap methods: another look at the jackknife. Ann Stat1979; 7: 1–26.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
